Literature DB >> 26464630

Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.

Nannan Pang1, Xianlin Duan1, Ming Jiang1, Jianhua Qu1, Hailong Yuan1, Jianli Xu1, Haizhou Cao1, Gang Chen1.   

Abstract

Related HLA-haploidentical HSCT has been applied more and more recently, but the reconstitution of T lymphocyte subsets and its clinical significance in patients received related HLA-haploidentical non T-cell depleted in vitro high-dose peripheral blood hematopoietic SCT (RHNT-PSCT) are incompletely defined. In the present study of our RHNT-PSCT, we found that in non-aGVHD group, CD3(+) T lymphocyte recovered to normal levels gradually between 60 and 90 days, and the recovery of CD4(+) T lymphocyte was retarded significantly, CD4(+)/CD8(+) ratio was apparently inverted. Whereas, the ratio of CD4(+) CD25(+) Foxp3(+) Treg cells was significantly lower in aGVHD group than in healthy control group and non-aGVHD group, and also in grade III-IV aGVHD patients than in grade I-II aGVHD patients. Meanwhile, we observed the level of interleukin-10 (IL-10) gradually increased in serum of patients without aGVHD, but decreased in III-IV aGVHD patients significantly. Spearman correlation analysis showed that serum IL-10 level was negatively correlated with the grade of aGVHD. These results suggest that the reconstitution of peripheral blood T lymphocyte subsets is good, and dynamic detection of Treg cells and serum IL-10 level might predict aGVHD in the early stage after our RHNT-PSCT.

Entities:  

Keywords:  Allo-HSCT; HLA-mismatched; acute GVHD; lymphocyte subsets; regulatory T-cell

Mesh:

Substances:

Year:  2015        PMID: 26464630      PMCID: PMC4583862     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

Review 1.  CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation.

Authors:  Emmanuel Zorn
Journal:  Semin Cancer Biol       Date:  2006-01-23       Impact factor: 15.707

Review 2.  Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.

Authors:  F Aversa
Journal:  Bone Marrow Transplant       Date:  2008-01-07       Impact factor: 5.483

3.  Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT.

Authors:  Judith Feucht; Kathrin Opherk; Peter Lang; Simone Kayser; Lena Hartl; Wolfgang Bethge; Susanne Matthes-Martin; Peter Bader; Michael H Albert; Britta Maecker-Kolhoff; Johann Greil; Hermann Einsele; Paul-Gerhardt Schlegel; Friedhelm R Schuster; Bernhard Kremens; Claudia Rossig; Bernd Gruhn; Rupert Handgretinger; Tobias Feuchtinger
Journal:  Blood       Date:  2015-01-23       Impact factor: 22.113

4.  Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease.

Authors:  K L Hippen; S C Merkel; D K Schirm; C Nelson; N C Tennis; J L Riley; C H June; J S Miller; J E Wagner; B R Blazar
Journal:  Am J Transplant       Date:  2011-05-12       Impact factor: 8.086

5.  Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.

Authors:  X-J Huang; D-H Liu; K-Y Liu; L-P Xu; H Chen; W Han; Y-H Chen; J-Z Wang; Z-Y Gao; Y-C Zhang; Q Jiang; H-X Shi; D-P Lu
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

6.  Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.

Authors:  Kyoo-Hyung Lee; Je-Hwan Lee; Jung-Hee Lee; Dae-Young Kim; Miee Seol; Young-Shin Lee; Young-Ah Kang; Mijin Jeon; Hyun-Ju Hwang; Ah-Rang Jung; Sung-Han Kim; Sung-Cheol Yun; Ho-Jin Shin
Journal:  Blood       Date:  2011-06-28       Impact factor: 22.113

7.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

Authors:  Dao-Pei Lu; Lujia Dong; Tong Wu; Xiao-Jun Huang; Mei-Jie Zhang; Wei Han; Huan Chen; Dai-Hong Liu; Zhi-Yong Gao; Yu-Hong Chen; Lan-Ping Xu; Yao-Chen Zhang; Han-Yun Ren; Dan Li; Kai-Yan Liu
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

8.  Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.

Authors:  John M Magenau; Xuemei Qin; Isao Tawara; Clare E Rogers; Carrie Kitko; Matthew Schlough; Daniel Bickley; Thomas M Braun; Pil-Sang Jang; Kathleen P Lowler; Dawn M Jones; Sung W Choi; Pavan Reddy; Shin Mineishi; John E Levine; James L M Ferrara; Sophie Paczesny
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-17       Impact factor: 5.742

9.  In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation.

Authors:  Yoshinobu Kanda; Kumi Oshima; Yuki Asano-Mori; Koji Kandabashi; Masahiro Nakagawa; Mamiko Sakata-Yanagimoto; Koji Izutsu; Akira Hangaishi; Shiho Tsujino; Seishi Ogawa; Toru Motokura; Shigeru Chiba; Hisamaru Hirai
Journal:  Transplantation       Date:  2005-05-27       Impact factor: 4.939

10.  Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism.

Authors:  Tatsuo Ichinohe; Takashi Uchiyama; Chihiro Shimazaki; Keitaro Matsuo; Shigehisa Tamaki; Masayuki Hino; Arata Watanabe; Motohiro Hamaguchi; Souichi Adachi; Hisashi Gondo; Nobuhiko Uoshima; Takao Yoshihara; Kazuo Hatanaka; Hiroshi Fujii; Keisei Kawa; Kazunobu Kawanishi; Koji Oka; Hideo Kimura; Mitsuru Itoh; Takeshi Inukai; Etsuko Maruya; Hiroh Saji; Yoshihisa Kodera
Journal:  Blood       Date:  2004-07-27       Impact factor: 22.113

View more
  4 in total

1.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Authors:  Reid W Merryman; Haesook T Kim; Pier Luigi Zinzani; Carmelo Carlo-Stella; Stephen M Ansell; Miguel-Angel Perales; Abraham Avigdor; Ahmad S Halwani; Roch Houot; Tony Marchand; Nathalie Dhedin; Willy Lescaut; Anne Thiebaut-Bertrand; Sylvie François; Aspasia Stamatoullas-Bastard; Pierre-Simon Rohrlich; Hélène Labussière Wallet; Luca Castagna; Armando Santoro; Veronika Bachanova; Scott C Bresler; Amitabh Srivastava; Harim Kim; Emily Pesek; Marie Chammas; Carol Reynolds; Vincent T Ho; Joseph H Antin; Jerome Ritz; Robert J Soiffer; Philippe Armand
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

2.  Peripheral blood Th9 cells reconstitution and its relationship with acute graft-versus-host disease after matched-sibling peripheral blood hematopoietic stem cell transplantation.

Authors:  Nannan Pang; Jianli Xu; Jianhua Qu; Xianlin Duan; Hailong Yuan; Gang Chen; Ming Jiang; Jianbing Ding
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

3.  [Comparisons of occurrence and curative effect of interstitial pneumonia after the related HLA-haploidentical and HLA-matched sibling peripheral blood hematopoietic stem cell transplantation].

Authors:  X Y Wang; M Jiang; J H Qu; X L Duan; H L Yuan; L Wang; J L Xu; L L Ding; Crimea Nadia Abdul; L Li; Arsene Eed; X H Guo; B Z Wen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-06-14

4.  Child with Wiskott-Aldrich syndrome underwent atypical immune reconstruction after umbilical cord blood transplantation: A case report.

Authors:  Bo-Han Li; Shao-Yan Hu
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.